You are here
Prescription medicines under evaluation
These applications for new medicines or new uses for existing medicines are currently under evaluation by the TGA. Evaluation does not guarantee registration or PBS entry.
Application types:
- Application type A: applications for a 'new medicine' containing a new active substance (new chemical entity or new biological entity) not currently approved in Australia
- Application type B: applications for a 'new combination', where two or more already approved medicines are combined into a single product
- Application type C: applications for a 'new indication', or additional therapeutic use, for an already approved medicine.
For more information visit Prescription medicines: applications under evaluation.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Application type
Sponsor
- AstraZeneca Pty Ltd (12)
- Merck Sharp & Dohme (Australia) Pty Ltd (9)
- Janssen-Cilag Pty Ltd (7)
- AbbVie Pty Ltd (6)
- Bristol-Myers Squibb Australia Pty Ltd (5)
- Amgen Australia Pty Ltd (4)
- Astellas Pharma Australia Pty Ltd (4)
- Seqirus Pty Ltd (4)
- Accelagen Pty Ltd (3)
- BeiGene AUS Pty Ltd (3)
- Boehringer Ingelheim Pty Ltd (3)
- GlaxoSmithKline Australia Pty Ltd (3)
- Novartis Pharmaceuticals Australia Pty Ltd (3)
- Roche Products Pty Ltd (3)
- UCB Australia Pty Ltd T/A UCB Pharma Division of UCB Australia (3)
- AFT Pharmaceuticals Pty Ltd (2)
- Amicus Therapeutics Pty Ltd (2)
- Aspen Pharmacare Australia Pty Ltd (2)
- Chiesi Australia Pty Ltd (2)
- Ipsen Pty Ltd (2)
- Novo Nordisk Pharmaceuticals Pty Ltd (2)
- Pfizer Australia Pty Ltd (2)
- Specialised Therapeutics Pharma Pty Ltd (2)
- Takeda Pharmaceuticals Australia Pty Ltd (2)
- Theramex Australia Pty Ltd (2)
- Vertex Pharmaceuticals Australia Pty Ltd (2)
- AA-Med Pty Ltd (1)
- Actor Pharmaceuticals Pty Ltd (1)
- Adjutor Healthcare Pty Ltd (1)
- Alexion Pharmaceuticals Australasia Pty Ltd (1)
- A Menarini Australia Pty Ltd (1)
- Amivas Australia Pty Ltd (1)
- Apellis Australia Pty Ltd (1)
- Arctic Vision Australia Pty Ltd (1)
- Argenx Australia Pty Ltd (1)
- Ballia Holdings Pty Ltd (1)
- Biogen Australia Pty Ltd (1)
- BioMarin Pharmaceutical Australia Pty Ltd (1)
- Celgene Pty Ltd (1)
- Cipla Australia Pty Ltd (1)
- CSL Behring Australia Pty Ltd (1)
- Eisai Australia Pty Ltd (1)
- Eli Lilly Australia Pty Ltd (1)
- Fresenius Medical Care Australia Pty Ltd (1)
- Galderma Australia Pty Ltd (1)
- Grifols Australia Pty Ltd (1)
- Guerbet Australia Pty Ltd (1)
- Jazz Pharmaceuticals ANZ Pty Ltd (1)
- Link Medical Products Pty Ltd T/A Link Pharmaceuticals (1)
- Lundbeck Australia Pty Ltd (1)
- Merz Australia Pty Ltd (1)
- Nexo Pharmaceuticals Pty Ltd (1)
- Norgine Pty Ltd (1)
- PTC THERAPEUTICS AUSTRALIA PTY LIMITED (1)
- Reach Pharmaceuticals Pty Ltd (1)
- Revance Australia Pty Ltd (1)
- Sanofi-Aventis Australia Pty Ltd (1)
- Servier Laboratories (Aust) Pty Ltd (1)
- Sun Pharma ANZ Pty Ltd (1)
- Swedish Orphan Biovitrum Pty Ltd (1)
- Technovalia Pty Ltd (1)
- Telix Pharmaceuticals (ANZ) Pty Ltd (1)
Results for
"[search-keyword]"
Search
130 result(s) found, displaying 1 to 25
-
Aug-2024Prescription medicine evaluationActive ingredient: Artesunate.
-
Jul-2024Prescription medicine evaluationActive ingredient: oxybutynin hydrochloride.
-
Jul-2024Prescription medicine evaluationActive ingredient: Botulinim toxin type a.
-
-
Jul-2024Prescription medicine evaluationActive ingredient: pegcetacoplan.
-
Jul-2024Prescription medicine evaluationActive ingredient: Influenza virus haemagglutinin.
-
Jul-2024Prescription medicine evaluationActive ingredient: Influenza virus haemagglutinin.
-
Jul-2024Prescription medicine evaluationActive ingredient: Canakinumab.
-
Jul-2024Prescription medicine evaluationActive ingredient: tarlatamab.
-
Jul-2024Prescription medicine evaluationActive ingredient: pembrolizumab.
-
Jul-2024Prescription medicine evaluationActive ingredient: pembrolizumab.
-
Jul-2024Prescription medicine evaluationActive ingredient: anacaulase-bcdb.
-
Jul-2024Prescription medicine evaluationActive ingredient: nivolumab.
-
Jul-2024Prescription medicine evaluationActive ingredient: macitentan.
-
Jul-2024Prescription medicine evaluationActive ingredient: .
-
Jul-2024Prescription medicine evaluationActive ingredient: omaveloxolone.
-
Jul-2024Prescription medicine evaluationActive ingredient: osimertinib mesilate.
-
Jul-2024Prescription medicine evaluationActive ingredient: tislelizumab.
-
-
Jul-2024Prescription medicine evaluationActive ingredient: Ipilimumab.
-
Jul-2024Prescription medicine evaluationActive ingredient: diclofenac sodium.
-
Jun-2024Prescription medicine evaluationActive ingredient: dupilumab.
-
May-2024Prescription medicine evaluationActive ingredient: Influenza virus haemagglutinin.
-
May-2024Prescription medicine evaluationActive ingredient: repotrectinib.
-
May-2024Prescription medicine evaluationActive ingredient: Influenza virus haemagglutinin.
Pages
- Current page 1
- Page 2
- Page 3
- Page 4
- Page 5
- Page 6
- Next page Next ›
- Last page Last »